144 related articles for article (PubMed ID: 35029156)
1. The COVID-19 Pandemic Highlights Opportunities to Improve Hepatocellular Carcinoma Screening and Diagnosis in a National Health System.
Kim NJ; Rozenberg-Ben-Dror K; Jacob DA; Berry K; Ioannou GN
Am J Gastroenterol; 2022 Apr; 117(4):678-684. PubMed ID: 35029156
[TBL] [Abstract][Full Text] [Related]
2. The road to pandemic recovery: Tracking COVID-19's impact on cirrhosis care and outcomes among 111,558 Veterans.
Adejumo AC; Yakovchenko V; Morgan TR; Spoutz P; Chia L; Bajaj JS; Chang MF; Dominitz JA; Rogal SS
Hepatology; 2023 Jun; 77(6):2016-2029. PubMed ID: 36705024
[TBL] [Abstract][Full Text] [Related]
3. Telephone-Only Visits Preserved Hepatocellular Cancer Screening Rates in Patients with Cirrhosis Early in the COVID-19 Pandemic.
Rudnick SR; Ugwuegbu J; Soufleris SJ; Bundy R; Dharod A; Russo MW
Dig Dis Sci; 2023 May; 68(5):1791-1796. PubMed ID: 36562886
[TBL] [Abstract][Full Text] [Related]
4. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
[TBL] [Abstract][Full Text] [Related]
5. Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis.
Kim NJ; Jacob DA; Ioannou GN; John BV; Rogal S; Rozenberg-Ben-Dror K
Am J Gastroenterol; 2021 Feb; 116(2):411-415. PubMed ID: 33252455
[TBL] [Abstract][Full Text] [Related]
6. Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Single Turkey Center Study.
Bilican G; Özgül S; Ekmen N; Moral K; Küçük H; Dumanlı S; Abiyev A; Karakan T; Kekilli M
J Gastrointestin Liver Dis; 2023 Sep; 32(3):367-370. PubMed ID: 37774229
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project.
Rogal SS; Taddei TH; Monto A; Yakovchenko V; Patton H; Merante M; Spoutz P; Chia L; Yudkevich J; Aytaman A; Rabiee A; John BV; Blechacz B; Cai CX; Gilles H; Shah AS; McCurdy H; Puri P; Jou J; Mazhar K; Dominitz JA; Anwar J; Morgan TR; Ioannou GN
Clin Gastroenterol Hepatol; 2024 Feb; 22(2):324-338. PubMed ID: 37460005
[TBL] [Abstract][Full Text] [Related]
8. Impact of the COVID-19 pandemic on liver transplant waitlist outcome in France.
Legeai C; Antoine C; Jasseron C; Kerbaul F; Dumortier J
Sci Rep; 2023 Jun; 13(1):9308. PubMed ID: 37291177
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic.
Serper M; Tapper EB; Kaplan DE; Taddei TH; Mahmud N
Am J Gastroenterol; 2023 Feb; 118(2):294-303. PubMed ID: 36114778
[TBL] [Abstract][Full Text] [Related]
11. Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review.
Akbulut S; Garzali IU; Hargura AS; Aloun A; Yilmaz S
J Gastrointest Cancer; 2023 Jun; 54(2):408-419. PubMed ID: 35499649
[TBL] [Abstract][Full Text] [Related]
12. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.
Davila JA; Henderson L; Kramer JR; Kanwal F; Richardson PA; Duan Z; El-Serag HB
Ann Intern Med; 2011 Jan; 154(2):85-93. PubMed ID: 21242365
[TBL] [Abstract][Full Text] [Related]
13. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey.
Chalasani N; Said A; Ness R; Hoen H; Lumeng L
Am J Gastroenterol; 1999 Aug; 94(8):2224-9. PubMed ID: 10445554
[TBL] [Abstract][Full Text] [Related]
14. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma.
Lu SN; Wang JH; Liu SL; Hung CH; Chen CH; Tung HD; Chen TM; Huang WS; Lee CM; Chen CC; Changchien CS
Cancer; 2006 Nov; 107(9):2212-22. PubMed ID: 17019738
[TBL] [Abstract][Full Text] [Related]
15. [Epidemiology, prevention, screening and diagnosis of hepatocellular carcinoma].
Trinchet JC; Alperovitch A; Bedossa P; Degos F; Hainaut P; Beers BV
Bull Cancer; 2009 Jan; 96(1):35-43. PubMed ID: 19211358
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.
Grecian SM; McLachlan S; Fallowfield JA; Kearns PKA; Hayes PC; Guha NI; Morling JR; Glancy S; Williamson RM; Reynolds RM; Frier BM; Zammitt NN; Price JF; Strachan MWJ
Liver Int; 2020 Sep; 40(9):2252-2262. PubMed ID: 32638496
[TBL] [Abstract][Full Text] [Related]
17. Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index.
Nartey YA; Awuku YA; Agyei-Nkansah A; Duah A; Bampoh SA; Ayawin J; Asibey SO; Björkström NK; Ye W; Afihene MY; Roberts LR; Plymoth A
BMC Gastroenterol; 2020 Dec; 20(1):428. PubMed ID: 33357229
[TBL] [Abstract][Full Text] [Related]
18. Negative impact of the pandemic on hospital admissions, morbidity and early mortality for acute cirrhosis decompensation.
Gananandan K; Phillips A; Chikhlia A; Old H; Sim SJY; Thakur N; Hussain I; Kazankov K; Mookerjee RP
BMJ Open Gastroenterol; 2023 Jan; 10(1):. PubMed ID: 36650007
[TBL] [Abstract][Full Text] [Related]
19. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
[TBL] [Abstract][Full Text] [Related]
20. The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL).
Okushin K; Tateishi R; Hirakawa S; Tachimori H; Uchino K; Nakagomi R; Yamada T; Nakatsuka T; Minami T; Sato M; Fujishiro M; Hasegawa K; Eguchi Y; Kanto T; Yoshiji H; Izumi N; Kudo M; Koike K
Sci Rep; 2024 Feb; 14(1):2826. PubMed ID: 38310156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
